[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=bb4d5c895bee785c5167b46e0b6d48fb85dfc93a2df4ce71cf53f75f8900b17a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754584320,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 136296566,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=bb4d5c895bee785c5167b46e0b6d48fb85dfc93a2df4ce71cf53f75f8900b17a"
    }
  },
  {
    "ts": null,
    "headline": "Ariel Global Fund Q2 2025 Commentary",
    "summary": "Arielâs non-consensus approach seeks to identify undervalued, out-of-favor, franchises that are misunderstood and therefore mispriced. Read more here.",
    "url": "https://finnhub.io/api/news?id=01afcc3f56b5e3e4cd9fdf0601a20b170ce890d05f541d233b77c511870d7d0d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754581500,
      "headline": "Ariel Global Fund Q2 2025 Commentary",
      "id": 136261061,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912015114/image_912015114.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Arielâs non-consensus approach seeks to identify undervalued, out-of-favor, franchises that are misunderstood and therefore mispriced. Read more here.",
      "url": "https://finnhub.io/api/news?id=01afcc3f56b5e3e4cd9fdf0601a20b170ce890d05f541d233b77c511870d7d0d"
    }
  },
  {
    "ts": null,
    "headline": "United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda",
    "summary": "The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a CAGR of 4.86% (2025-2033). Growth is driven by rising chronic diseases, demand for innovative medicines, and advanced biotech solutions. High R&D investments in oncology, neurology, and infectious diseases fuel the market, alongside robust government support and insurance coverage. California and New York lead in R&D and distribution. Key challenges include regulatory complex",
    "url": "https://finnhub.io/api/news?id=c5faab32289036b61d1de41f603a0cb2c73c4612692dcf7386f42a8f151806d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754570460,
      "headline": "United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda",
      "id": 136246157,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a CAGR of 4.86% (2025-2033). Growth is driven by rising chronic diseases, demand for innovative medicines, and advanced biotech solutions. High R&D investments in oncology, neurology, and infectious diseases fuel the market, alongside robust government support and insurance coverage. California and New York lead in R&D and distribution. Key challenges include regulatory complex",
      "url": "https://finnhub.io/api/news?id=c5faab32289036b61d1de41f603a0cb2c73c4612692dcf7386f42a8f151806d8"
    }
  },
  {
    "ts": null,
    "headline": "Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical",
    "summary": "The Saudi Arabia OTC Artificial Tears Market is projected to reach USD 79.09 million by 2033, growing at a CAGR of 4.22% from 2025. Contributing factors include a rising elderly population, increased incidence of dry eye syndrome, and greater use of digital screens. Enhanced awareness of eye health, expanding retail and online pharmacies, and favorable healthcare policies are also promoting market growth. Non-prescription artificial tears offer convenient solutions for mild to moderate condition",
    "url": "https://finnhub.io/api/news?id=09e8791d380db68c19a93903274690cc09b7fe501a69fed3d31134b08af60fcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754569860,
      "headline": "Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical",
      "id": 136246158,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Saudi Arabia OTC Artificial Tears Market is projected to reach USD 79.09 million by 2033, growing at a CAGR of 4.22% from 2025. Contributing factors include a rising elderly population, increased incidence of dry eye syndrome, and greater use of digital screens. Enhanced awareness of eye health, expanding retail and online pharmacies, and favorable healthcare policies are also promoting market growth. Non-prescription artificial tears offer convenient solutions for mild to moderate condition",
      "url": "https://finnhub.io/api/news?id=09e8791d380db68c19a93903274690cc09b7fe501a69fed3d31134b08af60fcd"
    }
  },
  {
    "ts": null,
    "headline": "REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights",
    "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2025.",
    "url": "https://finnhub.io/api/news?id=a0b549d231b9ad453be4bb927c3d02b0b58b575090f33c85ebd722e764d12223",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754564700,
      "headline": "REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights",
      "id": 136246171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2025.",
      "url": "https://finnhub.io/api/news?id=a0b549d231b9ad453be4bb927c3d02b0b58b575090f33c85ebd722e764d12223"
    }
  },
  {
    "ts": null,
    "headline": "REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy",
    "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery and a corresponding amendment to its eyecare collaboration with AbbVie.",
    "url": "https://finnhub.io/api/news?id=50a5fde4b6afc23dcca896011e5288b484edb544eb872a12f20810c7b182d203",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754564400,
      "headline": "REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy",
      "id": 136246172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery and a corresponding amendment to its eyecare collaboration with AbbVie.",
      "url": "https://finnhub.io/api/news?id=50a5fde4b6afc23dcca896011e5288b484edb544eb872a12f20810c7b182d203"
    }
  }
]